Preface
With the global prevalence of type 2 diabetes mellitus (T2DM) rising year by year, traditional treatments such as insulin and oral hypoglycemic drugs can control blood glucose in the short term but still cannot reverse disease progression.
In recent years, mesenchymal stem cell (MSC) therapy, due to its immune-modulating properties and potential for β-cell regeneration, has become a focal point of research in regenerative medicine for diabetes.
This study followed 61 T2DM patients with HbA1c ≥ 6.2% for up to 68 months after a single intravenous MSC injection, systematically evaluating the relationship between changes in HbA1c and MSC dosage, and analyzing the clinical responses of moderate-to-severe
Key Findings at a Glance
- Average HbA1c decreased from 7.49% before treatment to 6.7% (p < 0.0001)
- Moderate T2DM group (HbA1c 6.2–8%): average reduction of 0.58% (p < 0.0000002)
- Severe T2DM group (HbA1c > 8%): average reduction of 1.55% (p = 0.0122)
- Treatment effects persisted for more than three years, with no significant decline observed
- The high-dose MSC group (≥1 billion) showed a greater downward trend in HbA1c
Clinical Profile
A total of 61 participants were enrolled in the study, aged between 42 and 89 years, with Mesenchymal Stem Cells (MSC) doses ranging from 100 million to 2 billion cells.
Most patients received only a single intravenous MSC injection at Omotesando Helene Clinic, without interference from other adjunctive regenerative therapies. Across the full dataset, the efficacy rate showed no significant correlation with observation time (r = 0.041), indicating that the treatment effects could be stably maintained for several years without the need for repeated injections.
MSC Therapy details of type 2 diabetes
Mechanisms and Clinical Implications
MSCs may exert long-lasting metabolic effects through three main mechanisms:
- Paracrine effects—releasing repair factors such as IGF-1, TGF-β, and VEGF.
- Immune modulation—suppressing inflammatory cytokines (e.g., IL-6, TNF-α) and promoting Treg proliferation.
- Enhancement of β-cell function—increasing C-peptide levels and endogenous insulin secretion.
These mechanisms together contribute to the sustained therapeutic effects observed in this study, distinguishing MSC therapy from traditional drug treatments, which require long-term administration and are prone to fluctuating efficacy.
Conclusion and Outlook
This study is the first to demonstrate that, in patients with type 2 diabetes, a single high-dose intravenous MSC injection can achieve long-lasting blood glucose control. This disease-modifying intervention model marks a milestone shift in diabetes treatment strategies. Moving forward, further randomized controlled trials (RCTs) and immune mechanism tracking studies are needed to determine the optimal dosage, assess repeated administration strategies, and clarify the molecular basis of its long-term effects.
Importantly, no serious adverse events related to mesenchymal stem cell therapy were observed in this study, providing a safety assurance for its potential as a treatment option for chronic diseases. In severe diabetes patients, the reduction in HbA1c was particularly pronounced, highlighting MSC’s potential to correct metabolic dysregulation. From an immunological perspective, mesenchymal stem cells may help regulate the immune microenvironment, reducing chronic low-grade inflammation—a key factor in the progression of diabetes. In addition, their protective effects on vascular endothelial function, as well as their ability to promote microvascular regeneration and repair, may further lower the risk of diabetic complications such as diabetic foot, nephropathy, and retinopathy. These findings mark an important step forward in Cell and gene therapy.
Another notable highlight of this study is the “single-use” approach. For patients who find frequent clinic visits inconvenient or prefer low-intervention treatments, confirmation of the long-term benefits of one-time MSC therapy could greatly enhance treatment acceptance and compliance. At the same time, attention should be given to designing individualized treatment plans—based on factors such as BMI, insulin sensitivity, and biomarkers—to determine the optimal dosage and frequency, which will be key for the next phase of MSC application.
It is worth mentioning that although this study was retrospective, its long observation period, diverse patient composition, and clear dosage distribution provide a solid foundation for future prospective RCTs. By integrating molecular-level research with clinically stratified data, we may precisely identify the core mechanisms and target populations for MSC application in type 2 diabetes.
Overall, this study provides strong clinical evidence that even a single high-dose intravenous MSC infusion can maintain stable blood glucose improvement for over three years, with good safety and tolerability, offering highly valuable insights for future regenerative medicine strategies in diabetes.